Vir Biotechnology refiles prospectus supplement to add omitted exhibit
The company corrected its November 12 prospectus supplement filing after inadvertently omitting Exhibit 107, with no other changes to the stock offering terms.
SEC filing (2)
7 stories
The company corrected its November 12 prospectus supplement filing after inadvertently omitting Exhibit 107, with no other changes to the stock offering terms.
SEC filing (2)
Vir filed a preliminary prospectus supplement on November 12, 2026 to sell common stock, as the company advances its hepatitis delta and oncology pipelines.
SEC filing (3)
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
The company expanded its board from eight to nine members and named Dr. Topalian to fill the new seat and serve on its Science and Technology Committee.
SEC filing
Gilead gets exclusive rights to develop three masked T-cell engager candidates discovered by Vir, with a stock purchase alongside the agreement.
SEC filing
The PSMA-targeted T-cell engager, co-developed with Astellas, now has Fast Track status for late-line metastatic castration-resistant prostate cancer as Phase 3 plans target 2027.
SEC filing
Theravance Biopharma's former CFO takes over Vir's finance, IT and investor relations functions as Brent Sabatini steps down from interim duties.
SEC filing